retatrutide clinical trials safety efficacy Today, we shared new data from two Phase 3 of retatrutide, our investigational triple agonist. Learn more at our link in bio Perceived benefits of treatment for

As with all incretin-based therapies, retatrutide's side effect profile is closely linked to its receptor pharmacology

doi: 10.3389/fcvm.2021.754499 169 Wewer AlbrechtsenNJMllerAMartinussenCGluudLLRashuEBRichterMMet al

The 23-time Grand Slam champ explained to Oprah Winfrey that she was absolutely skeptical of using a GLP-1 medication to lose weight because others had framed the medicine as the easier route

You're getting the same active ingredient with less regulatory oversight

This sits within the broader story of GLP-1 and metabolic disease, which connects the receptor biology, drug discovery, and therapeutic pipeline behind the class